Clinical Trials

As part of the development process, our nuclear medicine investigational products are evaluated in clinical trials to find new and better ways to diagnose and treat disease. These studies may be sponsored by Advanced Accelerator Applications (AAA) or by independent investigators/physicians at medical centers.

Products tested in clinical trials may not be approved by health authorities, or they may be approved for certain indications but being tested to determine if they are useful in other conditions. Patients should discuss their potential participation in such studies with their physician. The table below lists oncology clinical trials and non-oncology clinical trials with our investigational products.

Please Select Compound
Select Disease State
AAA Sponsored
Investigator Sponsored
Study NumberStudy Name/TitlePhase
NCT01578239
Netter-1: Study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumors.

* Awaiting final analysis
III
NCT02230176
OCLURANDOM: Antitumor efficacy of PRRT with 177Lutetium Octreotate randomized vs sunitinib in unresectable progressive well-differentiated neuroendocrine pancreatic tumors
II
NCT03206060
Lutetium Lu 177 dotatate in therapy of inoperable pheochromocytoma (PHEO)/paraganglioma (PGL)
II
NCT03325816
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for patients with extensive-stage small cell lung cancer
I/II
Eudra CT N°: 2017-000369-54
LUTIA: Intra-arterial lutetium 177 dotatate for treatment of patients with neuroendocrine tumor liver metastases
II
NA
PREELU: Prediction of radio-exposure induced by patients treated by lutetium Lu 177 dotatate
Observational
NCT03490838 Eudra CT N°: 2017-004034-29
PROter: 177Lu-PSMA-R2 in patients with positive progressive, metastatic, castration resistant prostate cancer
I/II
in process
The diagnostic value of Ga 68 dotatate PET/CT in patients with cardiac sarcoidosis
I/II
NCT03448458
Gallium Ga 68 Dotatate PET/CT in diagnosing patients with metastatic castration resistant prostate cancer
II
NCT03602911
A comparison of NETSPOT (gallium Ga 68 dotatate) imaging versus F-FDG-PET in head and neck cancer patients
Proof of Concept
NCT03746847
PET imaging in patients with suspected cardiac sarcoidosis
Proof of Concept
NCT03490032
PROfind: 68Ga-PSMA-R2 in patients with biochemical relapse and metastatic prostate cancer
I/II
EudraCT N°: 2016-002053-38
MITIGATE: Study to evaluate 68Ga-NeoB PET/CT in patients with advanced TKI-treated gastrointestinal stromal tumors (GIST)

* NeoBOMB1 is now known as NeoB
I/IIa
Eudra CT N°: 2017-003432-37
NeoFIND: 68Ga-NeoB imaging in patients with malignancies known to overexpress Gastrin Releasing Peptide Receptor (GRPR)

* NeoBOMB1 is now known as NeoB
* Currently in Phase I
I/II